MedTrace Logo

Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)

NCT04645667 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2023-10-17

No results posted yet for this study

Summary

The purpose of this research study is to evaluate tacrolimus plasma concentrations in patients who will undergo an allogeneic hematopoietic stem cell transplant (HCT). The study aims to identify associations between plasma concentrations, baseline demographic characteristics, clinical lab parameters, and genetic factors. These associations will help clinicians determine the best starting dose for tacrolimus in order to minimize risks of aGVHD and tacrolimus-induced toxicities.

Conditions

  • Acute GVHD

Interventions

DRUG

Tacrolimus

Patients will be enrolled into this group if they receive tacrolimus per standard of care. This is an observational study and no interventions will be made.

Sponsors & Collaborators

  • University of North Carolina, Chapel Hill

    collaborator OTHER

  • UNC Lineberger Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Daniel J Crona, PharmD, PhD · UNC Lineberger Comprehensive Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2023-10-15
Completion
2023-10-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04645667 on ClinicalTrials.gov